Apple introduced the 12-inch MacBook. The first model ever to feature an Apple logo that didn’t light up. And since then, the ...

IO Biotech (IOBT) announced the publication of results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, in the Journal ...

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Evaxion Biotech (EVAX – Research Report), with a price target of $6.00. The company’s shares closed ...

Adam takes the lead in the show, which is reported to have cost $200million for the second season, and some viewers have ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

This year, when you watch Kendrick Lamar perform in the halftime show, it will likely be accompanied by a small Apple logo in the bottom-right corner – a privilege the tech giant paid $50 ...

Cognizant (Nasdaq: CTSH) announced an expanded agreement with Medidata, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, to provide support for ...

Biotech stocks are companies that use living organisms to make drugs and vaccines. Often, they merge cutting-edge technology with new findings in molecular science and virology to treat life ...

While 2024 was a “challenging” year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months. On November 28 ...

Merck's (NYSE:MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer candidate LM-299 in a deal worth up to $3.3B underscores Big Pharma's appetite for best-in-class assets ...

The J.P. Morgan Healthcare Conference in San Francisco is back for 2025 and here at Fierce Biotech, we’re going to bring you all the latest updates live from the life sciences event of the year.